AI Summary
→ WHAT IT COVERS Carlos Carrillo, a drug development veteran with nearly three decades of experience, outlines the operational, regulatory, and cultural shifts biotechs must execute when transitioning from clinical stage to commercial launch, covering partner governance, compliance infrastructure, quality unit structure, and the leadership mindset required to scale sustainably. → KEY INSIGHTS - **Commercial readiness timing:** Begin building commercial infrastructure no later than late Phase 2, not at Phase 3 or pre-submission. This applies across supply chain, regulatory strategy, and market access planning. Biotechs with expedited designations like breakthrough therapy face compressed timelines that leave no room for late-stage organizational buildout, making early preparation non-negotiable. - **Quality unit structure:** QA and QC must operate under a single unified quality unit with one reporting line. Separating them into different reporting structures — such as placing QC under operations — creates a regulatory conflict of interest and has directly resulted in FDA Form 483 observations. This structural decision affects inspection readiness across the entire commercial lifecycle. - **Partner evaluation framework:** Evaluate external partners — CROs, CDMOs, consultants — by selecting three to five candidates maximum, reviewing therapeutic and phase-specific case studies, testing operational agility through scenario questions, and embedding incentive clauses for timely quality execution in contracts. Never outsource strategic decision-making, only execution. Assign internal accountable owners per partner relationship beyond procurement. - **Compliance as continuous operation:** Regulators expect inspection readiness every day, not only at submission. Biotechs should run external GMP audits before every major milestone, embed ALCOA-plus data integrity principles into every process from the start, stress-test commercial batch simulations before engineering batches, and treat CAPA systems as part of the go-to-market plan rather than a post-approval corrective tool. - **Speed versus scalability balance:** A one-month launch delay can represent up to half a billion dollars in lost revenue in certain therapeutic areas. However, cutting corners to accelerate timelines generates recalls, compliance gaps, and supply disruptions that cost more time than they save. Biotechs should invest in modular manufacturing platforms, digital supply chains, and pre-negotiated surge capacity to achieve both velocity and durability simultaneously. → NOTABLE MOMENT Carrillo warns that a failed launch by a smaller biotech does not only damage that single company — it can erode investor and payer confidence across an entire therapeutic modality or technology platform, creating industry-wide consequences that extend far beyond one organization's commercial setback. 💼 SPONSORS None detected 🏷️ Biotech Commercialization, Regulatory Affairs, Clinical-to-Commercial Transition, Quality Assurance, Launch Readiness